Journal Article (Review Article)

DKFZ-2019-01278

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond.

Platten, M. (First author)DKFZ* ; Nollen, E. A. A. ; Röhrig, U. F. ; Fallarino, F. ; Opitz, C. (Last author)DKFZ*

2019
Nature Publ. Group London

This record in other databases:  

Please use a persistent id in citations: doi:10.1038/s41573-019-0016-5

Abstract: L-Tryptophan (Trp) metabolism through the kynurenine pathway (KP) is involved in the regulation of immunity, neuronal function and intestinal homeostasis. Imbalances in Trp metabolism in disorders ranging from cancer to neurodegenerative disease have stimulated interest in therapeutically targeting the KP, particularly the main rate-limiting enzymes indoleamine-2,3-dioxygenase 1 (IDO1), IDO2 and tryptophan-2,3-dioxygenase (TDO) as well as kynurenine monooxygenase (KMO). However, although small-molecule IDO1 inhibitors showed promise in early-stage cancer immunotherapy clinical trials, a phase III trial was negative. This Review summarizes the physiological and pathophysiological roles of Trp metabolism, highlighting the vast opportunities and challenges for drug development in multiple diseases.

---

Contributing Institute(s):

1. Neuroimmunologie und Hirntumorimmunologie (D170)
2. Metabolischer Crosstalk bei Krebserkrankungen (B350)
3. DKTK Heidelberg (L101)

Research Program(s):

1. 312 - Functional and structural genomics (POF3-312) (POF3-312)

Appears in the scientific report 2019

---

Database coverage:
; ; BIOSIS Previews ; BIOSIS Reviews Reports And Meetings ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; IF >= 50 ; JCR ; NCBI Molecular Biology Database ; Nationallizenz ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---